TMDX vs XRAY Stock Comparison
XRAY currently leads TMDX in this stock comparison, with AIQ scores of 51 vs 39. The clearest difference is value, while TMDX has the stronger quality profile.
What is the main difference between TMDX and XRAY?
XRAY leads the current stock comparison as DENTSPLY SIRONA Inc., with the clearest separation coming from value and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
TransMedics Group, Inc. vs DENTSPLY SIRONA Inc.
XRAY leads
XRAY leads by 12 AIQ points, primarily on Value and Momentum, and the lead has widened from 3 points over 30 sessions. Wall Street currently favors TMDX on target upside.
Competitive: 4 of 6 evidence groups support XRAY, its lead is widening, and its current signal state is conflicted.
TransMedics Group, Inc.
DENTSPLY SIRONA Inc.
The Algovestiq AIQ Score currently favors XRAY over TMDX, 51 versus 39 as of Oct 31, 2026. XRAY's advantage is driven primarily by stronger value and momentum, while TMDX holds the stronger quality profile. XRAY also shows the stronger technical structure relative to its 50-day moving average, though analyst target upside currently favors TMDX. 4 of 6 covered evidence groups favor XRAY today, and the comparison is rated Competitive on stability: the leader is throwing conflicting signals. XRAY lead: Strengthening — the AIQ differential moved from 3 to 12 points over 30 sessions.
Compare TransMedics Group, Inc. and DENTSPLY SIRONA Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Total return with distributions reinvested, from daily closes.
Total return comparison
Growth of $10,000, distributions reinvested
Split-adjusted closes; each distribution is reinvested at the close on its ex-dividend date. Taxes and trading costs are not modeled.
Compare TMDX and XRAY against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Value32 vs 73XRAY +41
- Quality64 vs 27TMDX +37
- Momentum23 vs 53XRAY +30
- Risk Resilience31 vs 51XRAY +20
4 of 6 evidence groups favor XRAY. XRAY’s edge is concentrated in value and momentum; TMDX keeps a meaningful quality edge.
What changed since the last close
Latest scored session 2026-10-28, compared against the prior scored session 2026-10-27.
No factor moved materially.
New signals
- Keltner Channel Breakdown — bearish, volatility, short horizon
Largest factor move: Momentum -1, not enough on its own to move the overall score.
No signal started or stopped since the prior session; its 5 active signals are unchanged.
XRAY's lead was unchanged in the latest session.
Deeper signal detail for each name lives on its own signals page — TMDX and XRAY both carry a full feed there.
The central trade-off
XRAY (DENTSPLY SIRONA Inc.): the stronger current systematic profile, led by value and momentum.
TMDX (TransMedics Group, Inc.): the counter-case, on quality, fundamentals, analyst expectations — but at materially higher volatility, 49.2% against 39.4%.
The AIQ Score and Wall Street therefore point in different directions on this pair.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
XRAYXRAY on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
TMDXTMDX on combined revenue and EPS growth.
Value
XRAYXRAY on the peer-relative Value factor, by 41 points.
Momentum
XRAYXRAY on the Momentum factor, by 30 points.
Lower downside
XRAYXRAY on Risk Resilience, by 20 points.
Analyst upside
TMDXTMDX on implied upside to the consensus price target.
AIQ vs Wall Street
The model and the Street disagree here: AIQ favors XRAY, analyst targets favor TMDX. That disagreement is the most useful thing on this page.
| Measure | TMDX | XRAY | Note |
|---|---|---|---|
| Implied upside to target | +55.4% | +28.8% | TMDX has more room |
| Target dispersion | +75.1% | +65.2% | Lower is tighter analyst agreement |
| Consensus | Buy | Hold | Context, not a primary driver |
| Analysts covering | 8 | 7 | Higher coverage generally improves confidence |
The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
4 of 6 covered evidence groups favor XRAY. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | XRAY | 39 vs 51 |
| Fundamentals | TMDX | revenue growth 9.2% vs 2%; EPS growth 100% vs 4.6%; TTM ROE 33% vs -39.8%; gross margin 58.7% vs 49.5%; operating margin 12.2% vs 11.7% |
| Valuation | XRAY | Value 32 vs 73 |
| Technicals | XRAY | Price vs 50-day -20.2% vs -2.3%; vs 200-day -29.8% vs -16.9% |
| Risk Resilience | XRAY | Risk Resilience 31 vs 51 |
| Analyst expectations | TMDX | Target upside 55.4% vs 28.8% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of TMDX and XRAY and are excluded from the count.
AIQ Decision Stability
The two are close enough that your objective, not the score, should decide.
- The AIQ gap is wide at 12 points. (supports the conclusion holding)
- The leader's advantage has been widening. (supports the conclusion holding)
- The leader is throwing conflicting signals. (argues the conclusion is provisional)
- Analyst targets on the leader are widely dispersed. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on XRAY.
How the comparison changed
120 daily snapshots · Jun 29 – Oct 28XRAY lead: Strengthening — the AIQ differential moved from 3 to 12 points over 30 sessions.
- Today
- XRAY +12
- 39 vs 51
- 7 sessions ago
- XRAY +13
- 39 vs 52
- 30 sessions ago
- XRAY +3
- 41 vs 44
- 90 sessions ago
- TMDX +8
- 51 vs 43
The lead changed hands 3 times in this window, most recently on Sep 28 when XRAY moved ahead of TMDX.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
1 bullish / 4 bearish / 1 neutral, conflicted
Only TMDX
- Keltner Channel Breakdown — bearish, volatility, short horizon
- RSI Oversold - Potential Bounce — bullish, momentum, short horizon
- MACD Bearish Crossover — bearish, momentum, short horizon
1 bullish / 2 bearish / 2 neutral, conflicted
Only XRAY
- Bollinger Band Squeeze — neutral, volatility, short horizon
- MACD Bullish Crossover — bullish, momentum, short horizon
Both carry 3 more signals that do not separate them: Death Cross Active, ATR Expansion - Breakout Mode, Downtrend Structure Active.
XRAY leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -1.68%, AIQ 0 points).
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -0.83%, AIQ 0 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1TMDX closes the Value gap — currently 41 points behind, the largest single contributor to XRAY's edge.
- 2TMDX's Death Cross Active resolves — a bearish trend rule currently active against it.
- 3XRAY's conflicting signal state resolves bearish — it currently carries 1 bullish and 2 bearish rules at once.
- 4A regime shift changes factor weighting — Quality and Value carry the heaviest weights in the composite, so a rotation toward either would move the result most.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
TMDX leads on balance| Metric | TMDX | XRAY |
|---|---|---|
| Revenue growth (YoY) | 9.2% | 2% |
| EPS growth (YoY) | 100% | 4.6% |
| Gross margin | 58.7% | 49.5% |
| Operating margin | 12.2% | 11.7% |
| Return on equity (TTM) | 33% | -39.8% |
| Debt to equity | 1.67 | 1.71 |
Performance
XRAY leads 5 of 6 windows| Metric | TMDX | XRAY |
|---|---|---|
| 1 week (5 sessions) | -7.6% | 4% |
| 1 month (20 sessions) | -19.8% | 6.5% |
| 3 months (63 sessions) | -12.1% | -31.3% |
| 6 months (126 sessions) | -32.1% | -17.8% |
| Year to date | -45% | -17.4% |
| 1 year (252 sessions) | -47.1% | -28% |
Technicals
XRAY has the stronger structure| Metric | TMDX | XRAY |
|---|---|---|
| RSI (14) | 25.4 | 62.9 |
| ADX (14) | 29 | 27.8 |
| Price vs 50-day | -20.2% | -2.3% |
| Price vs 200-day | -29.8% | -16.9% |
| Volatility (1M, annualized) | 49.2% | 39.4% |
Risk
XRAY is the more resilient| Metric | TMDX | XRAY |
|---|---|---|
| Beta | 1.09 | 1.14 |
| Sharpe ratio | -0.93 | -0.53 |
| Sortino ratio | -1.24 | -0.84 |
| Max drawdown | -58.8% | -42.6% |
| Current drawdown | -55.5% | -35.7% |
| Annualized volatility | 57.3% | 47.9% |
| Value at risk (95%) | -5.5% | -4.3% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, TMDX or XRAY?
On the Algovestiq AIQ Score, XRAY is the stronger of the two as of Oct 31, 2026, scoring 51 against TMDX's 39. The edge comes from value and momentum. TMDX is not without a case — it holds the better quality profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is TMDX or XRAY the better buy right now?
XRAY carries the stronger systematic profile as of Oct 31, 2026, and the comparison is rated Competitive — 4 of 6 covered evidence groups agree. A Competitive rating means the two are close enough that your objective, not the score, should decide.
Why does the AIQ Score favor XRAY over TMDX?
The composite weights Quality, Value, Momentum and Risk Resilience. XRAY leads Value by 41 points; TMDX leads Quality by 37 points; XRAY leads Momentum by 30 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, TMDX or XRAY?
Analyst price targets imply +55.4% upside for TMDX and +28.8% for XRAY, so the Street currently favors TMDX. That points the opposite way to the AIQ Score, which favors XRAY. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, TMDX or XRAY?
XRAY is the better-valued of the two on the peer-relative Value factor. XRAY on the peer-relative Value factor, by 41 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, TMDX or XRAY?
TMDX on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, TMDX or XRAY?
XRAY on the Momentum factor, by 30 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, TMDX or XRAY?
XRAY is the more resilient of the two, so the other name carries the higher downside risk. XRAY on Risk Resilience, by 20 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is TMDX more profitable than XRAY?
TMDX leads on the comparable margin measures — gross margin 58.7% vs 49.5%; operating margin 12.2% vs 11.7%; ttm roe 33% vs -39.8%.
Is XRAY's lead over TMDX getting stronger or weaker?
XRAY lead: Strengthening — the AIQ differential moved from 3 to 12 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-06-29 and 2026-10-28. The lead has changed hands 3 times in that window, most recently on 2026-09-28, when XRAY moved ahead of TMDX.
What would change the TMDX vs XRAY verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: TMDX closes the Value gap — currently 41 points behind, the largest single contributor to XRAY's edge; TMDX's Death Cross Active resolves — a bearish trend rule currently active against it; XRAY's conflicting signal state resolves bearish — it currently carries 1 bullish and 2 bearish rules at once; a regime shift changes factor weighting — Quality and Value carry the heaviest weights in the composite, so a rotation toward either would move the result most.
What do the current signals say about TMDX and XRAY?
TMDX: 1 bullish / 4 bearish / 1 neutral, conflicted. XRAY: 1 bullish / 2 bearish / 2 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on TMDX is Death Cross Active (bearish, long horizon). On XRAY it is Death Cross Active (bearish, long horizon).
Compare TMDX and XRAY with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.